VolitionRX Ltd宣布,其创新产品Nu.q在获得报销批准后,预计将于2026年第四季度在法国正式进入常规临床应用阶段。这一进展标志着公司在推动癌症早期检测技术普及方面迈出关键一步。
VolitionRX Ltd宣布,其创新产品Nu.q在获得报销批准后,预计将于2026年第四季度在法国正式进入常规临床应用阶段。这一进展标志着公司在推动癌症早期检测技术普及方面迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.